BACKGROUND: The effects of continuous positive airway pressure (CPAP) for obstructive sleep apnoea (OSA) on insulin resistance are not clear. Trials have found conflicting results and no appropriate control groups have been used. METHODS:Forty-two men with known type 2 diabetes and newly diagnosed OSA (>10 dips/h in oxygen saturation of >4%) were randomised to receive therapeutic (n = 20) or placebo CPAP (n = 22) for 3 months. Baseline tests were performed and repeated after 3 months. The study was double blind. RESULTS: Results are expressed as mean (SD). CPAP improved the Epworth sleepiness score significantly more in the therapeutic group than in the placebo group (-6.6 (4.5) vs -2.6 (4.9), p = 0.01). The maintenance of wakefulness test improved significantly in the therapeutic group but not in the placebo group (+10.6 (13.9) vs -4.7 (11.8) min, p = 0.001). Glycaemic control and insulin resistance did not significantly change in either the therapeutic or placebo groups: HbA1c (-0.02 (1.5) vs +0.1 (0.7), p = 0.7, 95% CI -0.6% to +0.9%), euglycaemic clamp (M/I: +1.7 (14.1) vs -5.7 (14.8), p = 0.2, 95% CI -1.8 to +0.3 l/kg/min(1000)), HOMA-%S (-1.5 (2.3) vs -1.1 (1.8), p = 0.2, 95% CI -0.3% to +0.08%) and adiponectin (-1.1 (1.2) vs -1.1 (1.3), p = 0.2, 95% CI -0.7 to +0.6 microg/ml). Body mass index, bioimpedance and anthropometric measurements were unchanged. Hours of CPAP use per night were 3.6 (2.8) in the treatment group and 3.3 (3.0) in the placebo group (p = 0.8). There was no correlation between CPAP use and the measures of glycaemic control or insulin resistance. CONCLUSION: Therapeutic CPAP does not significantly improve measures of glycaemic control or insulin resistance in men with type 2 diabetes and OSA.
RCT Entities:
BACKGROUND: The effects of continuous positive airway pressure (CPAP) for obstructive sleep apnoea (OSA) on insulin resistance are not clear. Trials have found conflicting results and no appropriate control groups have been used. METHODS: Forty-two men with known type 2 diabetes and newly diagnosed OSA (>10 dips/h in oxygen saturation of >4%) were randomised to receive therapeutic (n = 20) or placebo CPAP (n = 22) for 3 months. Baseline tests were performed and repeated after 3 months. The study was double blind. RESULTS: Results are expressed as mean (SD). CPAP improved the Epworth sleepiness score significantly more in the therapeutic group than in the placebo group (-6.6 (4.5) vs -2.6 (4.9), p = 0.01). The maintenance of wakefulness test improved significantly in the therapeutic group but not in the placebo group (+10.6 (13.9) vs -4.7 (11.8) min, p = 0.001). Glycaemic control and insulin resistance did not significantly change in either the therapeutic or placebo groups: HbA1c (-0.02 (1.5) vs +0.1 (0.7), p = 0.7, 95% CI -0.6% to +0.9%), euglycaemic clamp (M/I: +1.7 (14.1) vs -5.7 (14.8), p = 0.2, 95% CI -1.8 to +0.3 l/kg/min(1000)), HOMA-%S (-1.5 (2.3) vs -1.1 (1.8), p = 0.2, 95% CI -0.3% to +0.08%) and adiponectin (-1.1 (1.2) vs -1.1 (1.3), p = 0.2, 95% CI -0.7 to +0.6 microg/ml). Body mass index, bioimpedance and anthropometric measurements were unchanged. Hours of CPAP use per night were 3.6 (2.8) in the treatment group and 3.3 (3.0) in the placebo group (p = 0.8). There was no correlation between CPAP use and the measures of glycaemic control or insulin resistance. CONCLUSION: Therapeutic CPAP does not significantly improve measures of glycaemic control or insulin resistance in men with type 2 diabetes and OSA.
Authors: Y Miyazaki; A Mahankali; M Matsuda; L Glass; S Mahankali; E Ferrannini; K Cusi; L J Mandarino; R A DeFronzo Journal: Diabetes Care Date: 2001-04 Impact factor: 19.112
Authors: Igor Alexander Harsch; Simin Pour Schahin; Kerstin Brückner; Martin Radespiel-Tröger; Florian S Fuchs; Eckhart Georg Hahn; Peter Christopher Konturek; Tobias Lohmann; Joachim Hans Ficker Journal: Respiration Date: 2004 May-Jun Impact factor: 3.580
Authors: Eileen R Chasens; Charles W Atwood; Lora E Burke; Mary Korytkowski; Robert Stansbury; Patrick J Strollo; Susan M Sereika Journal: Contemp Clin Trials Date: 2018-12-02 Impact factor: 2.226
Authors: Abd A Tahrani; Asad Ali; Neil T Raymond; Safia Begum; Kiran Dubb; Shanaz Mughal; Biju Jose; Milan K Piya; Anthony H Barnett; Martin J Stevens Journal: Am J Respir Crit Care Med Date: 2012-06-21 Impact factor: 21.405
Authors: Ioannis Papaioannou; Michael Patterson; Gillian L Twigg; Ali Vazir; Mohammad Ghatei; Mary J Morrell; Michael I Polkey Journal: J Clin Sleep Med Date: 2011-10-15 Impact factor: 4.062
Authors: Ari Shechter; Gary D Foster; Wei Lang; David M Reboussin; Marie-Pierre St-Onge; Gary Zammit; Anne B Newman; Richard P Millman; Thomas A Wadden; John M Jakicic; Elsa S Strotmeyer; Rena R Wing; F Xavier Pi-Sunyer; Samuel T Kuna Journal: J Sleep Res Date: 2017-05-31 Impact factor: 3.981